glp 1 breast cancer Study links GLP-1 drugs to lower diagnosis rates Semaglutide decelerates the growth and

It is also one of the most frustrating aspects of practicing obesity medicine

( 10.1016/j.jacbts.2022.08.002) [DOI] [PMC free article] [PubMed] [Google Scholar] Pyke C Heller RS Kirk RK Orskov C Reedtz-Runge S Kaastrup P Hvelplund A Bardram L Calatayud D & Knudsen LB

[2024] found no difference in cognitive performance in 7 IIH patients treated with exenatide compared to 8 patients treated with placebo ( Table 3 )

This is not a replacement for prescribed medical treatment for any other health condition

And its time to let that narrative go, once and for all

As a GLP-1RA medication, semaglutide interacts with the brain's appetite control center to induce feelings of fullness, making it the go-to weight-loss drug